We here studied primary cells derived from an aggressive TP53 mutant and chemoresistant ALK‐rearranged tumor that exhibited region‐specific EMT features to identify novel/effective combination treatments to treat ALK‐rearranged NSCLC. This evidence concerns the gene TP53 and non-small cell lung carcinoma.